Aspirin + Paclitaxel for Head and Neck Cancer
(APAC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a phase II trial of aspirin and paclitaxel in patients with recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) who have received prior platinum and PD-1 inhibitor treatment and have an alteration in the PI3K pathway.
Who Is on the Research Team?
Brendan Knapp, MD
Principal Investigator
Washington University School of Medicine
Are You a Good Fit for This Trial?
This trial is for people with head and neck squamous cell carcinoma that has come back or spread, who have already been treated with platinum drugs and PD-1 inhibitors, and whose cancer shows a change in the PI3K pathway.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Aspirin
- Paclitaxel
Trial Overview
The study is testing if adding aspirin to paclitaxel (a chemotherapy drug) helps treat this type of cancer. All participants receive both medicines. This is a phase II clinical trial.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Paclitaxel will be given intravenously over the course of 60 minutes on an outpatient basis on Days 1, 8, 15, and 22 of each 28-day cycle. Aspirin will be administered on an outpatient basis and taken each day of a 28-day cycle.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.